A new AI tool is removing the biggest barrier to drug discovery: the need to speak fluent computer code. Insilico Medicine, a clinical-stage biotech company powered by generative artificial intelligence (AI), launched PandaClaw in March 2026, a feature that lets biologists conduct sophisticated drug research by simply typing questions in plain English, without requiring specialized computational training. What's the Real Problem PandaClaw Solves? The traditional drug discovery field has long faced a talent bottleneck. Companies need "bilingual" professionals, fluent in both biology and artificial intelligence, to unlock AI's potential. Training these rare experts often takes longer than building the software itself. PandaClaw bridges this gap by automating the translation between what biologists want to know and what AI systems can compute. Instead of hiring expensive computational specialists or forcing biologists to learn programming, researchers can now ask questions naturally and let the AI handle the technical heavy lifting. The tool operates through an autonomous workflow that mirrors how experienced biologists actually think. When a researcher submits a research objective in plain language, PandaClaw's agent core breaks it down into distinct analytical tasks, pulls data from over 1,000 bioinformatics tools and 140 specialized scientific skills, and delivers high-quality, figure-rich reports with full data transparency. "PandaClaw is far more than a sophisticated search engine; it is a comprehensive autonomous agent designed to mirror the logic and expertise of seasoned biologists and bioinformaticians," stated Dr. Frank Pun, Head of Insilico Medicine Hong Kong. Dr. Frank Pun, Head of Insilico Medicine Hong Kong How Does PandaClaw Actually Work for Researchers? - Natural Language Interface: Researchers type questions or research objectives in everyday language, eliminating the need to write code or understand computational workflows. - Multi-Step Autonomous Workflow: The AI agent automatically formulates a multi-step analytical plan, parses requests into distinct tasks, and selects optimal tools from an expansive toolkit of over 1,000 bioinformatics resources. - Real-Time Data Integration: The system aggregates and cross-references multi-omics datasets by drawing from the PandaOmics platform, internal data warehouses, external biological databases, and proprietary user data simultaneously. - Self-Correction and Validation: PandaClaw autonomously diagnoses and corrects formatting issues or data anomalies within an isolated sandbox environment to ensure scientific integrity before delivering results. - Transparent Reporting: The platform produces detailed reports with robust statistical validation, deep biological annotation, and complete data provenance tracking for reproducibility. How Fast Can AI Actually Accelerate Drug Discovery? The speed gains are striking. Traditional early-stage drug discovery typically requires an average of 4.5 years from project start to identifying a viable drug candidate. Insilico has nominated 20 preclinical candidates between 2021 and 2024, with an average timeline of just 12 to 18 months per program, using only 60 to 200 molecules synthesized and tested in each program. That represents a reduction of roughly 70 percent in development time compared to conventional approaches. This acceleration matters because drug discovery is expensive and time-consuming. Every year a promising therapy spends in the lab is a year patients with serious diseases wait for treatment. By compressing the preclinical phase, PandaClaw could help get more candidates into human trials faster, potentially bringing new medicines to patients sooner. What Makes This Different From Previous AI Drug Discovery Tools? PandaClaw represents the latest evolution in Insilico's broader push toward what the company calls "pharmaceutical superintelligence." The journey began in March 2023 with ChatPandaGPT, which enabled natural language interaction with scientific literature and knowledge graphs. It progressed in July 2024 with Ask Panda, an internal tool that allowed researchers to query target identification results within the platform. Now, PandaClaw emerges as a fully realized biological analysis agent capable of executing complex tasks, bridging computational results with mechanistic interpretation, and delivering real-time insights through simple natural language commands. The key difference is accessibility. Previous AI tools in drug discovery required researchers to understand the underlying computational architecture. PandaClaw abstracts away that complexity entirely. A biologist can ask "What genes are dysregulated in this disease pathway?" and the system handles the data retrieval, statistical analysis, and biological interpretation without requiring the researcher to write a single line of code. The tool integrates three core components designed to work seamlessly together. The Agent Core is modeled on the workflow-driven logic of experienced biologists. Proprietary Data Warehouses are curated by cross-disciplinary teams of data scientists and biologists. A Skills library is built on the analytical reasoning of veteran bioinformaticians. Together, these components create a system that thinks like a human expert but operates at machine speed. What Does This Mean for the Future of Drug Development? If PandaClaw and similar tools continue to mature, the bottleneck in drug discovery may shift. Instead of waiting for rare computational talent, companies could focus on recruiting strong biologists and letting AI handle the data-intensive analysis. This could democratize drug discovery, allowing smaller biotech firms and academic labs to compete with larger pharmaceutical companies that traditionally had more computational resources. Insilico is already applying this approach across multiple therapeutic areas. The company is developing drugs for fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. The company also extends its AI platform, Pharma.AI, across diverse industries including advanced materials, agriculture, nutritional products, and veterinary medicine. This breadth suggests that the underlying technology is flexible enough to tackle different types of biological problems. The launch of PandaClaw also comes as Insilico continues to mature as a company. The biotech firm was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code HKEX: 03696, signaling investor confidence in its AI-driven drug discovery model.
